(BSX) Boston Scientific - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1011371077

Stents, Catheters, Pacemakers, Defibrillators, Stimulators

Stock: Health Care Equipment
Age 33.7y

MCap 130,610m
Avg Vol 7.40M (705M USD)

Beta 0.647
Volatility 25.01%

EPS (Earnings per Share)

EPS CAGR: 14.59%
EPS Trend: 96.8%

Last SUE: 2.12
Qual. Beats: 11

Revenue

Rev. CAGR: 13.72%
Rev. Trend: 97.9%

Last SUE: 2.10
Qual. Beats: 8

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	25.0%
Value at Risk 5%th	38.1%
Relative Tail Risk	-7.28%

Reward TTM
Sharpe Ratio	-0.44
Alpha	-18.92
CAGR/Max DD	1.43

Character TTM
Hurst Exponent	0.476
Beta	0.647
Beta Downside	0.716

Drawdowns 3y
Max DD	18.56%
Mean DD	3.23%
Median DD	1.85%

Description: BSX Boston Scientific December 02, 2025

Boston Scientific (BSX) designs, manufactures and markets a broad portfolio of interventional medical devices across two main segments-MedSurg and Cardiovascular-serving specialties such as gastroenterology, urology, neuromodulation, cardiac rhythm management, and peripheral vascular care. The company’s product slate includes endoscopic clips, biliary stents, single-use duodenoscopes, ureteral stents, holmium laser systems, spinal cord stimulators, the WATCHMAN FLX left-atrial appendage closure device, and a range of implantable cardiac monitors and defibrillators.

Key recent metrics: BSX reported FY 2023 revenue of $12.3 billion, with the Cardiovascular segment contributing roughly 55 % of total sales and delivering a 22 % operating margin, while MedSurg grew at a 7 % CAGR over the past three years driven by demand for single-use devices. R&D spending remained steady at about 7 % of revenue, supporting a pipeline that includes next-generation leadless pacing and AI-enabled remote monitoring solutions. Macro-level drivers include an aging U.S. population, rising prevalence of chronic cardiovascular disease, and a sustained shift toward minimally invasive, outpatient procedures that favor disposable device formats.

For a deeper quantitative dive, you might explore the ValueRay platform’s detailed valuation models for BSX.

Piotroski VR‑10 (Strict, 0-10) 8.5

Net Income: 2.79b TTM > 0 and > 6% of Revenue
FCF/TA: 0.09 > 0.02 and ΔFCF/TA 3.68 > 1.0
NWC/Revenue: 13.99% < 20% (prev 17.92%; Δ -3.93% < -1%)
CFO/TA 0.11 > 3% & CFO 4.63b > Net Income 2.79b
Net Debt (10.20b) to EBITDA (4.68b): 2.18 < 3
Current Ratio: 1.51 > 1.5 & < 3
Outstanding Shares: last quarter (1.50b) vs 12m ago 0.54% < -2%
Gross Margin: 65.05% > 18% (prev 0.62%; Δ 6443 % > 0.5%)
Asset Turnover: 47.90% > 50% (prev 41.78%; Δ 6.12% > 0%)
Interest Coverage Ratio: 6.57 > 6 (EBITDA TTM 4.68b / Interest Expense TTM 403.0m)

Altman Z'' 1.50

A: 0.06 (Total Current Assets 8.04b - Total Current Liabilities 5.33b) / Total Assets 42.71b
B: 0.11 (Retained Earnings 4.90b / Total Assets 42.71b)
C: 0.07 (EBIT TTM 2.65b / Avg Total Assets 40.39b)
D: 0.26 (Book Value of Equity 4.92b / Total Liabilities 19.08b)
Altman-Z'' Score: 1.50 = BB

Beneish M -2.98

DSRI: 0.93 (Receivables 2.83b/2.50b, Revenue 19.35b/15.91b)
GMI: 0.96 (GM 65.05% / 62.41%)
AQI: 1.05 (AQ_t 0.71 / AQ_t-1 0.68)
SGI: 1.22 (Revenue 19.35b / 15.91b)
TATA: -0.04 (NI 2.79b - CFO 4.63b) / TA 42.71b)
Beneish M-Score: -2.98 = A

ValueRay F-Score (Strict, 0-100) 73.28

1. Piotroski: 8.50pt
2. FCF Yield: 2.69%
3. FCF Margin: 19.51%
4. Debt/Equity: 0.48
5. Debt/Ebitda: 2.18
6. ROIC - WACC: -1.36%
7. RoE: 12.42%
8. Revenue Trend: 97.92%
9. EPS Trend: 96.84%

What is the price of BSX shares?

As of January 25, 2026, the stock is trading at USD 92.51 with a total of 13,613,135 shares traded.
Over the past week, the price has changed by +5.04%, over one month by -3.73%, over three months by -9.65% and over the past year by -8.98%.

Is BSX a buy, sell or hold?

Boston Scientific has received a consensus analysts rating of 4.59. Therefore, it is recommended to buy BSX.

Strong Buy: 23
Buy: 8
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the BSX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	124.4	34.5%
Analysts Target Price	124.4	34.5%
ValueRay Target Price	104.1	12.5%

BSX Fundamental Data Overview January 21, 2026

P/E Trailing = 47.0963
P/E Forward = 25.3807
P/S = 6.7502
P/B = 5.5828
P/EG = 0.8591
Revenue TTM = 19.35b USD
EBIT TTM = 2.65b USD
EBITDA TTM = 4.68b USD
Long Term Debt = 10.99b USD (from longTermDebt, last quarter)
Short Term Debt = 483.0m USD (from shortLongTermDebt, last quarter)
Debt = 11.15b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 10.20b USD (from netDebt column, last quarter)
Enterprise Value = 140.48b USD (130.61b + Debt 11.15b - CCE 1.27b)
Interest Coverage Ratio = 6.57 (Ebit TTM 2.65b / Interest Expense TTM 403.0m)
EV/FCF = 37.21x (Enterprise Value 140.48b / FCF TTM 3.77b)
FCF Yield = 2.69% (FCF TTM 3.77b / Enterprise Value 140.48b)
FCF Margin = 19.51% (FCF TTM 3.77b / Revenue TTM 19.35b)
Net Margin = 14.41% (Net Income TTM 2.79b / Revenue TTM 19.35b)
Gross Margin = 65.05% ((Revenue TTM 19.35b - Cost of Revenue TTM 6.76b) / Revenue TTM)
Gross Margin QoQ = 69.93% (prev 67.65%)
Tobins Q-Ratio = 3.29 (Enterprise Value 140.48b / Total Assets 42.71b)
Interest Expense / Debt = 0.78% (Interest Expense 87.0m / Debt 11.15b)
Taxrate = 19.49% (183.0m / 939.0m)
NOPAT = 2.13b (EBIT 2.65b * (1 - 19.49%))
Current Ratio = 1.51 (Total Current Assets 8.04b / Total Current Liabilities 5.33b)
Debt / Equity = 0.48 (Debt 11.15b / totalStockholderEquity, last quarter 23.39b)
Debt / EBITDA = 2.18 (Net Debt 10.20b / EBITDA 4.68b)
Debt / FCF = 2.70 (Net Debt 10.20b / FCF TTM 3.77b)
Total Stockholder Equity = 22.45b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.90% (Net Income 2.79b / Total Assets 42.71b)
RoE = 12.42% (Net Income TTM 2.79b / Total Stockholder Equity 22.45b)
RoCE = 7.91% (EBIT 2.65b / Capital Employed (Equity 22.45b + L.T.Debt 10.99b))
RoIC = 6.33% (NOPAT 2.13b / Invested Capital 33.63b)
WACC = 7.70% (E(130.61b)/V(141.76b) * Re(8.30%) + D(11.15b)/V(141.76b) * Rd(0.78%) * (1-Tc(0.19)))
Discount Rate = 8.30% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.63%
[DCF Debug] Terminal Value 82.25% ; FCFF base≈3.05b ; Y1≈3.76b ; Y5≈6.41b
Fair Price DCF = 70.93 (EV 115.39b - Net Debt 10.20b = Equity 105.18b / Shares 1.48b; r=7.70% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 96.84 | EPS CAGR: 14.59% | SUE: 2.12 | # QB: 11
Revenue Correlation: 97.92 | Revenue CAGR: 13.72% | SUE: 2.10 | # QB: 8
EPS next Quarter (2026-03-31): EPS=0.80 | Chg30d=-0.000 | Revisions Net=+1 | Analysts=21
EPS next Year (2026-12-31): EPS=3.47 | Chg30d=+0.003 | Revisions Net=+6 | Growth EPS=+14.4% | Growth Revenue=+11.6%

Additional Sources for BSX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle